BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sacco R, Mismas V, Romano A, Bertini M, Bertoni M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Giacomelli L, Marceglia S, Bargellini I. Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients. World J Hepatol 2015; 7(1): 33-39 [PMID: 25624994 DOI: 10.4254/wjh.v7.i1.33] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Darnell A, Belmonte E, Reig M, Brú C. Evaluating the response to locoregional and systemic treatment for hepatocellular carcinoma. Radiologia (Engl Ed) 2018;60:424-36. [PMID: 30196841 DOI: 10.1016/j.rx.2018.05.004] [Reference Citation Analysis]
2 Afshar M, Fletcher P, Bardoli AD, Ma YT, Punia P. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget 2018;9:16988-95. [PMID: 29682199 DOI: 10.18632/oncotarget.24769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 N'Kontchou G, Nault JC, Sutter O, Bourcier V, Coderc E, Grando V, Nahon P, Ganne-Carrié N, Diallo A, Sellier N, Seror O. Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results. Liver Cancer 2019;8:172-85. [PMID: 31192154 DOI: 10.1159/000489319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
4 Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. Eur Radiol 2021;31:2737-46. [PMID: 33123796 DOI: 10.1007/s00330-020-07381-9] [Reference Citation Analysis]
5 Kim H, Yu SJ, Yeo I, Cho YY, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Lee S, Jun J, Park T, Yoon JH, Kim Y. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). Mol Cell Proteomics 2017;16:1312-23. [PMID: 28550167 DOI: 10.1074/mcp.M116.066704] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Teixeira AC, Brasil IRC, Torres AFC, Tavora F. The Evaluation of Angiogenesis Markers in Hepatocellular Carcinoma and Precursor Lesions in Liver Explants From a Single Institution. Appl Immunohistochem Mol Morphol 2018;26:330-6. [PMID: 27556821 DOI: 10.1097/PAI.0000000000000426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Zhan Y, Zhou F, Yu X, Luo F, Liu F, Liang P, Cheng Z, Han Z, Yu J. Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation. International Journal of Hyperthermia 2018;35:105-11. [DOI: 10.1080/02656736.2018.1483533] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]